Download PATHOGEN SAFETY DATA SHEET Herpes Simplex Virus

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Influenza A virus wikipedia , lookup

HIV wikipedia , lookup

Human cytomegalovirus wikipedia , lookup

Trichinosis wikipedia , lookup

Norovirus wikipedia , lookup

Leptospirosis wikipedia , lookup

Neonatal infection wikipedia , lookup

Pandemic wikipedia , lookup

Hospital-acquired infection wikipedia , lookup

Orthohantavirus wikipedia , lookup

West Nile fever wikipedia , lookup

Hepatitis C wikipedia , lookup

Ebola virus disease wikipedia , lookup

Hepatitis B wikipedia , lookup

Middle East respiratory syndrome wikipedia , lookup

Chickenpox wikipedia , lookup

Marburg virus disease wikipedia , lookup

Henipavirus wikipedia , lookup

Sexually transmitted infection wikipedia , lookup

Lymphocytic choriomeningitis wikipedia , lookup

Herpes simplex research wikipedia , lookup

Herpes simplex wikipedia , lookup

Herpes simplex virus wikipedia , lookup

Transcript
Office of Research
Compliance
PATHOGEN SAFETY DATA SHEET
Herpes Simplex Virus
CHARACTERISTICS
Morphology
Growth Conditions
HSV-1 and HSV-2 are members of the Herpesviridea
family. Are double stranded DNA viruses enclosed
within an icosahedral capsid.
Cell Culture
HEALTH HAZARDS
Host Range
Modes of
Transmission
Signs and
Symptoms
Humans
Direct contact with infected secretions or mucous
membranes or skins with lesions.
Cold sores: Mainly caused by HSV-1.
Gingivostomatitis, fever, sore throat, mucosal edema,
and painful lesions
Genital herpes: Sexually transmitted disease mainly
caused by HSV-2. Bilateral, painful, and extensive
genital ulcers, which heal without scarring within 12
days.
Infectious Dose
Incubation Period
Unknown.
1 to 26 days.
MEDICAL PRECAUTIONS/TREATMENT
Prophylaxis
Vaccines
None
None
Treatment
Surveillance
MSU Requirements
Antiviral drugs like acyclovir, foscarnet valacyclovir,
famciclovir, and penciclovir.
Monitor for symptoms.
Report any exposures.
LABORATORY HAZARDS
Laboratory
Acquired Infections
(LAIs)
None.
Sources
Virus is shed from saliva, cervix, and urethra.
CONTAINMENT REQUIREMENTS
BSL2
For all procedures involving known or potentially
infected cultures.
ABSL2
For all procedures utilizing infected animals
SPILL PROCEDURES
Small
Notify others working in the lab. Remove and don
new PPE. Cover area of the spill with absorbent
material and add 10 % Bleach. Allow 30 minutes
hour of contact time. After 30 minutes and then
cleanup and dispose of materials.
Large
For assistance, contact MSU's Biosafety Officer (406994-6998) or Safety and Risk Management (406-9942711).
EXPOSURE PROCEDURES
Mucous membrane
Other Exposures
Reporting
Medical Follow-up
VIABILITY
Flush eyes, mouth or nose for 5 minutes at eyewash
station.
Wash area with soap and water for 5 minutes.
Immediately report incident to supervisor, complete
a first report of injury report, and submit to Safety
and Risk Management.
During business hours:
Montana Occupational Health
2075 Charlotte St. Suite 3
Bozeman, MT
After business hours:
Bozeman Deaconess Hospital
Emergency Room
915 Highland Blvd
Bozeman, MT
Disinfection
Susceptible to 10 % Bleach, and 70 % ethanol.
Inactivation
Inactivated by dry heat (1 hour at 160-170oC).
SUPPLEMENTAL REFERENCES
Survival Outside Host
Unknown.
Canadian MSDS:
PERSONAL PROTECTIVE EQUIPMENT (PPE)
BMBL:5th Edition
CDC
http://www.phac-aspc.gc.ca/lab-bio/res/psdsftss/index-eng.php
http://www.cdc.gov/biosafety/publications/bmbl5/BM
BL.pdf
http://www.cdc.gov/std/herpes/stdfact-herpes.htm
Minimum PPE
Requirements
Additional
Precautions
At minimum, gloves, closed toed shoes, lab coat,
and appropriate face and eye protection prior to
working with Herpes Simplex Virus. Additional PPE
may be required depending on lab specific SOPs.
None.